HK1034902A1 - Fluoxetine enteric pellets - Google Patents

Fluoxetine enteric pellets

Info

Publication number
HK1034902A1
HK1034902A1 HK01105581A HK01105581A HK1034902A1 HK 1034902 A1 HK1034902 A1 HK 1034902A1 HK 01105581 A HK01105581 A HK 01105581A HK 01105581 A HK01105581 A HK 01105581A HK 1034902 A1 HK1034902 A1 HK 1034902A1
Authority
HK
Hong Kong
Prior art keywords
enteric pellets
fluoxetine
fluoxetine enteric
pellets
enteric
Prior art date
Application number
HK01105581A
Other languages
English (en)
Inventor
Neil Robert Anderson
Roger Garrick Harrison
Daniel Frederick Lynch
Peter Lloyd Oren
Original Assignee
Company Lilly Corporate Ct Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25349313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1034902(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Company Lilly Corporate Ct Ind filed Critical Company Lilly Corporate Ct Ind
Publication of HK1034902A1 publication Critical patent/HK1034902A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HK01105581A 1997-05-29 2001-08-10 Fluoxetine enteric pellets HK1034902A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/867,196 US5910319A (en) 1997-05-29 1997-05-29 Fluoxetine enteric pellets and methods for their preparation and use

Publications (1)

Publication Number Publication Date
HK1034902A1 true HK1034902A1 (en) 2001-11-09

Family

ID=25349313

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01105581A HK1034902A1 (en) 1997-05-29 2001-08-10 Fluoxetine enteric pellets

Country Status (46)

Country Link
US (3) US5910319A (sv)
JP (1) JP3210288B2 (sv)
KR (1) KR100549473B1 (sv)
CN (2) CN1161109C (sv)
AR (1) AR011728A1 (sv)
AT (1) AT408068B (sv)
AU (1) AU726690B2 (sv)
BE (1) BE1011925A3 (sv)
BR (1) BR9801989A (sv)
CA (1) CA2234826C (sv)
CH (1) CH693018A5 (sv)
CO (1) CO4940407A1 (sv)
CZ (1) CZ290582B6 (sv)
DE (1) DE19823940B4 (sv)
DK (1) DK176776B1 (sv)
ES (1) ES2161574B1 (sv)
FI (1) FI119971B (sv)
FR (1) FR2763846B1 (sv)
GB (1) GB2325623B (sv)
GR (1) GR980100188A (sv)
HK (1) HK1034902A1 (sv)
HU (1) HUP9800882A3 (sv)
ID (1) ID20343A (sv)
IL (1) IL124073A (sv)
IT (1) ITMI980908A1 (sv)
LT (1) LT4477B (sv)
LU (1) LU90245B1 (sv)
LV (1) LV12176B (sv)
MY (1) MY118139A (sv)
NL (1) NL1009259C2 (sv)
NO (1) NO317743B1 (sv)
NZ (1) NZ330192A (sv)
PE (1) PE75399A1 (sv)
PL (1) PL192293B1 (sv)
PT (1) PT102152B (sv)
RO (1) RO120043B1 (sv)
RS (1) RS49827B (sv)
RU (1) RU2164405C2 (sv)
SE (1) SE522914C2 (sv)
SG (1) SG72805A1 (sv)
SI (1) SI9800128B (sv)
SV (1) SV1998000052A (sv)
TR (1) TR199800937A3 (sv)
TW (1) TWI239838B (sv)
UA (1) UA48193C2 (sv)
ZA (1) ZA983173B (sv)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
CA2698347A1 (en) * 1999-05-20 2000-11-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
ATE318135T1 (de) * 1999-09-03 2006-03-15 Apbi Holdings Llc Verwendung von dapoxetin, a selektiver serotonin- aufnahme inhibitor mit schnellem wirkungseintritt,zur behandlung von sexueller dysfunction
CN1094347C (zh) * 1999-11-15 2002-11-20 广东药学院药物研究所 一种治疗前列腺良性增生症的控释微丸及其制备方法
US6273260B1 (en) 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
JP4181738B2 (ja) * 2000-08-25 2008-11-19 信越化学工業株式会社 腸溶性コーティング製剤の製造方法
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
WO2002038126A2 (en) * 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
US20040170688A1 (en) * 2001-08-06 2004-09-02 Deshmukh Abhijit Mukund Enteric formulation of fluoxetin
WO2003013480A1 (en) 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004058228A1 (en) * 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
US8614247B2 (en) * 2003-04-10 2013-12-24 Institut National De La Sante Et De La Recherche Medicale Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof
GEP20084406B (en) 2003-05-30 2008-06-25 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
US20050176693A1 (en) * 2003-08-12 2005-08-11 Boissonneault Roger M. Method of intermittent administration of a pharmaceutical for the treatment of conditions associated with a female's menstrual cycle
EP1699458A4 (en) * 2003-12-30 2012-04-25 Reddys Lab Ltd Dr PHARMACEUTICAL COMPOSITION
AU2005237360B2 (en) * 2004-04-30 2010-10-21 Astellas Pharma Inc. Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
WO2006071868A2 (en) * 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
WO2007015270A2 (en) * 2005-08-02 2007-02-08 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
CA2629800A1 (en) * 2005-11-23 2007-05-31 Thomas G. Gant Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
EP1825847A3 (en) * 2006-02-24 2008-01-23 Teva Pharmaceutical Industries Ltd Fluvastatin sodium pharmaceutical compositions
CN101057837B (zh) * 2006-04-20 2010-12-22 湖南九典制药有限公司 一种右旋酮洛芬肠溶微丸及制备方法
WO2007134168A2 (en) * 2006-05-10 2007-11-22 Dr. Reddy's Laboratories Ltd. Process for preparing duloxetine
WO2007139886A2 (en) * 2006-05-22 2007-12-06 Teva Pharmaceutical Industries Ltd. Duloxetine hydrochloride delayed release formulations
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー. 複式ユニット製薬的製剤
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
RU2009106681A (ru) * 2006-07-28 2010-09-10 Др.Редди`С Лабораторис Лтд. (In) Гранулированные фармацевтические композиции
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
WO2008036846A2 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
US20090226517A1 (en) * 2008-02-06 2009-09-10 Vinita Umashankar Vyas Pharmaceutical formulations comprising duloxetine
AP2975A (en) 2008-07-16 2014-09-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
WO2010026993A1 (ja) * 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
CN101804145B (zh) * 2009-02-12 2012-11-14 杭州赛利药物研究所有限公司 一种大蒜油肠溶微丸胶囊及其制备方法
MX2012003082A (es) * 2009-09-17 2012-04-19 Cadila Healthcare Ltd Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
ES2706880T3 (es) * 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
CA2870134C (en) * 2012-05-02 2020-04-28 Capsugel France SAS Aqueous dispersions of hydroxypropyl methylcellulose acetate succinate (hpmcas)
CN102716084B (zh) * 2012-06-29 2013-09-25 海南美大制药有限公司 盐酸氟西汀脂质体固体制剂
BR112015004190A2 (pt) 2012-09-03 2017-07-04 Daiichi Sankyo Co Ltd composição farmacêutica de liberação sustentada, e, método para produzir uma composição farmacêutica de liberação sustentada
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9782356B2 (en) 2014-05-20 2017-10-10 Dow Global Technologies Llc Capsule shells comprising an esterified cellulose ether
JP6190078B2 (ja) * 2014-05-20 2017-08-30 ダウ グローバル テクノロジーズ エルエルシー 部分的に中和されたエステル化セルロースエーテルを含む分散体
WO2015187874A1 (en) * 2014-06-07 2015-12-10 Structure-Ase, Inc. A method for the detection and/or diagnosis of eating disorders and malnutrition using x-ray diffraction
US10471152B2 (en) 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
CA3096453A1 (en) 2017-04-13 2018-10-18 Chase Therapeutics Corporation Pharmaceutical combination comprising fluoxetine and pramipexole and its use for treating synucleinopathies
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
CN107898942B (zh) * 2017-11-24 2021-01-26 一力制药(罗定)有限公司 一种感冒清热胶囊及其制备方法
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2022115054A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Enteric coated duloxetine compositions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
JPS517116A (en) 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CH649216A5 (de) 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4444778A (en) * 1981-08-27 1984-04-24 Coughlin Shaun R Method and composition for treating atherosclerosis
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4847092A (en) * 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4918242A (en) 1988-03-30 1990-04-17 Aldrich Chemical Company, Inc. Novel optically 1,3-phenoxypropylhalides
CA1337955C (en) * 1988-09-26 1996-01-23 Thomas A. Almquist Recoating of stereolithographic layers
US4999382A (en) * 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
JPH04202124A (ja) * 1990-11-29 1992-07-22 Fuji Kagaku Kogyo Kk 噴霧乾燥造粒法による薬物放出の制御された製剤の製造法
WO1992013452A1 (en) * 1991-02-04 1992-08-20 Young James W Methods of use and compositions of r(-) fluoxetine
HUT69390A (en) * 1991-05-07 1995-09-28 Dynagen Inc Controlled, sustained release delivery system for smoking cessation
ATE173159T1 (de) * 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
JPH06293633A (ja) * 1993-04-05 1994-10-21 Shin Etsu Chem Co Ltd 水性腸溶性エマルジョンの製造方法
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
CA2175494C (en) * 1993-11-03 2000-09-19 Young W. Cho Microparticular pharmaceutical compositions
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
JPH08109126A (ja) * 1994-10-07 1996-04-30 Amano Pharmaceut Co Ltd 耐衝撃性腸溶性顆粒剤およびこれを含有する錠剤
JPH08245423A (ja) * 1995-03-06 1996-09-24 Shionogi & Co Ltd 水系腸溶性コーティング液
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
IL124073A (en) 2002-02-10
USRE39030E1 (en) 2006-03-21
CA2234826C (en) 2000-12-19
TR199800937A2 (xx) 1999-10-21
LU90245B1 (fr) 2002-07-31
HU9800882D0 (en) 1998-05-28
LT4477B (lt) 1999-03-25
UA48193C2 (uk) 2002-08-15
LV12176A (lv) 1998-12-20
FI980846A0 (fi) 1998-04-16
TR199800937A3 (tr) 1999-10-21
LV12176B (en) 1999-03-20
AT408068B (de) 2001-08-27
CN1285189A (zh) 2001-02-28
NO982197D0 (no) 1998-05-14
DK176776B1 (da) 2009-08-10
ITMI980908A1 (it) 1999-10-28
GB9807939D0 (en) 1998-06-10
HUP9800882A2 (hu) 2000-03-28
CZ114398A3 (cs) 1998-12-16
CN1161109C (zh) 2004-08-11
NL1009259C2 (nl) 1998-12-01
GR980100188A (el) 1999-01-29
AR011728A1 (es) 2000-08-30
CO4940407A1 (es) 2000-07-24
MY118139A (en) 2004-09-30
BE1011925A3 (fr) 2000-03-07
BR9801989A (pt) 2000-02-08
FI980846A (sv) 1998-11-30
ES2161574A1 (es) 2001-12-01
NZ330192A (en) 1999-08-30
RS49827B (sr) 2008-08-07
FR2763846A1 (fr) 1998-12-04
LT98058A (en) 1998-10-26
CZ290582B6 (cs) 2002-08-14
ID20343A (id) 1998-12-03
SI9800128A (sl) 1999-02-28
RU2164405C2 (ru) 2001-03-27
SV1998000052A (es) 1999-03-16
IE980284A1 (en) 2000-07-12
KR100549473B1 (ko) 2006-03-23
CH693018A5 (de) 2003-01-31
US5985322A (en) 1999-11-16
PT102152B (pt) 2000-09-29
AU726690B2 (en) 2000-11-16
LU90245A1 (sv) 1998-11-30
PT102152A (pt) 1998-12-31
SE522914C2 (sv) 2004-03-16
GB2325623A (en) 1998-12-02
ES2161574B1 (es) 2002-06-16
JP3210288B2 (ja) 2001-09-17
ZA983173B (en) 1999-10-15
CA2234826A1 (en) 1998-11-29
SE9801336D0 (sv) 1998-04-17
DE19823940A1 (de) 1998-12-03
YU16598A (en) 1999-11-22
SI9800128B (sl) 2000-04-30
US5910319A (en) 1999-06-08
FR2763846B1 (fr) 2001-05-18
DE19823940B4 (de) 2010-04-29
PE75399A1 (es) 1999-08-17
PL192293B1 (pl) 2006-09-29
GB2325623B (en) 1999-04-14
RO120043B1 (ro) 2005-08-30
FI119971B (sv) 2009-05-29
NO982197L (no) 1998-11-30
SG72805A1 (en) 2000-05-23
AU6904898A (en) 1998-12-03
CN1200924A (zh) 1998-12-09
CN1212834C (zh) 2005-08-03
JPH10330253A (ja) 1998-12-15
KR19980086622A (ko) 1998-12-05
SE9801336L (sv) 1998-11-30
HUP9800882A3 (en) 2000-07-28
TWI239838B (en) 2005-09-21
NO317743B1 (no) 2004-12-13
ATA93198A (de) 2001-01-15
PL326134A1 (en) 1998-12-07

Similar Documents

Publication Publication Date Title
GB2325623B (en) Fluoxetine enteric pellets
PL339733A1 (en) Fodder
GB9705926D0 (en) Improved document completion
PL334476A1 (en) Reactor
GB2344584B (en) Digester
GB9704660D0 (en) Oil-slick containment
GB9721053D0 (en) Software guardcard
GB9700014D0 (en) Interface
PL106005U1 (en) Reactor
AU133945S (en) Reactor
TW310689U (en) Improved regenerator
CA82556S (en) Capsule
TW331908U (en) Improved undervalve
GB9726744D0 (en) Improved weatherbar
GB9827955D0 (en) Improved weatherbar
TW322694U (en) Improved buoy
TW334796U (en) Improved Hula-hoop structure
TW334786U (en) Improved bathbrush structure
TW317333U (en) Improved voltmeter-ammeter structure
TW333808U (en) Improved jardiniere structure
TW361584U (en) Improved structure for fast couplings
HU9701411D0 (en) Swelling
TW330562U (en) Improved sealing can
GB9712826D0 (en) Enyzme
GB9714421D0 (en) Structural elements

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130424